Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 7/20 | 0.51 |
| ▸ | PARP3 | Q9Y6F1 | 11/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16227584 | 0.90 | PARP1 (0.63) | PARP1PARP2PARP3CYP1A1CYP2D6 | |
| SCHEMBL853576 | 0.90 | PARP1 (0.55) | PARP1PARP2PARP3SCN9ACYP1A1 | |
| SCHEMBL853588 | 0.90 | BCHE (0.41) | PARP1PARP2SCN9ACYP1A1CYP2D6 | |
| SCHEMBL15467547 | 0.89 | PARP1 (0.51) | PARP1PARP2PARP3 | |
| SCHEMBL16227249 | 0.89 | PARP1 (0.67) | PARP1PARP2PARP3SCN9A | |
| SCHEMBL16227242 | 0.89 | PARP1 (0.64) | PARP1PARP2PARP3SCN9ACYP1A1 | |
| SCHEMBL16227155 | 0.88 | PARP1 (0.61) | PARP1PARP2PARP3SCN9ACYP1A1 | |
| SCHEMBL16227250 | 0.87 | PARP1 (0.67) | PARP1PARP2PARP3CYP1A1CYP2D6 | |
| SCHEMBL15468106 | 0.84 | PARP1 (0.53) | PARP1PARP2PARP3CYP1A1CYP2D6 | |
| SCHEMBL16227005 | 0.84 | PARP1 (0.68) | PARP1PARP2PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993594-B2 | Isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-20140045846-A1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-13 | — | — | US | disclosed |
| EP-2432765-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133647-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045846-A1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.